Literature DB >> 8621907

Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway.

K L Rock1, K Clark.   

Abstract

By conjugation of proteins to beads, Ags can be selectively targeted into the MHC class I pathway of phagocytes in vivo and can stimulate CTL responses. Because phagocytes also present particulate Ag on MHC class II molecules, we examined whether these Ags stimulated concomitant CD4 T cell immunity. Although the priming of CD4 T cells with soluble OVA required adjuvants, particulate Ag was stimulatory when injected in saline. We next examined whether CD4 T cell responses played a role in the generation of CTL to particulate Ag. At low concentrations of Ag, OVA primed CTLs in wild-type mice but not in MHC class II-deficient animals, indicating that MHC class II presentation of Ag was essential for CTL generation. These data both support a model where CD4 T cells collaborate with CTLs as part of a three-cell interaction and identify a phagocyte as the third cell in this reaction. Interestingly, injection of higher concentrations of the same Ag primed equivalent CTL responses in both wild-type and MHC class II-deficient mice. These results indicate that a key variable in determining whether CTL generation is helper cell dependent or independent is the dose of immunogen. This may explain in part why CTL responses to abundant Ags, such as viruses, tend to be helper independent, while responses to less abundant Ags, such as minor histocompatibility Ags, require T helper cells. In addition, these results also point to the potential of using particulate Ags to prime or boost responses in settings with CD4 immunodeficiency.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8621907

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity.

Authors:  C Sedlik; G Dadaglio; M F Saron; E Deriaud; M Rojas; S I Casal; C Leclerc
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

Review 2.  Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells.

Authors:  Steven De Vleeschouwer; Stefaan W Van Gool; Frank Van Calenbergh
Journal:  Childs Nerv Syst       Date:  2004-09-28       Impact factor: 1.475

3.  Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles.

Authors:  Hong Shen; Anne L Ackerman; Virginia Cody; Alessandra Giodini; Ella R Hinson; Peter Cresswell; Richard L Edelson; W Mark Saltzman; Douglas J Hanlon
Journal:  Immunology       Date:  2006-01       Impact factor: 7.397

4.  Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis.

Authors:  N Seo; Y Tokura; T Nishijima; H Hashizume; F Furukawa; M Takigawa
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

5.  Tumor vaccine against recurrence of hepatocellular carcinoma.

Authors:  Bao-Gang Peng; Li-Jiang Liang; Qiang He; Ming Kuang; Jia-Ming Lia; Ming-De Lu; Jie-Fu Huang
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

6.  Administration of superantigens protects mice from lethal Listeria monocytogenes infection by enhancing cytotoxic T cells.

Authors:  S Okamoto; S Kawabata; I Nakagawa; S Hamada
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

Review 7.  An approach to the identification of T cell epitopes in the genomic era: application to Francisella tularensis.

Authors:  Michael Valentino; John Frelinger
Journal:  Immunol Res       Date:  2009-02-11       Impact factor: 2.829

Review 8.  Overview of current immunotherapeutic strategies for glioma.

Authors:  Anda-Alexandra Calinescu; Neha Kamran; Gregory Baker; Yohei Mineharu; Pedro Ricardo Lowenstein; Maria Graciela Castro
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

9.  Vaccine adjuvants - Current status and prospects on controlled release adjuvancity.

Authors:  S M Sivakumar; Mohammed M Safhi; M Kannadasan; N Sukumaran
Journal:  Saudi Pharm J       Date:  2011-06-25       Impact factor: 4.330

10.  Mycobacterium avium subsp. paratuberculosis fibronectin attachment protein activates dendritic cells and induces a Th1 polarization.

Authors:  Jun Sik Lee; Sung Jae Shin; Michael T Collins; In Duk Jung; Young-Il Jeong; Chang-Min Lee; Yong Kyoo Shin; Daejin Kim; Yeong-Min Park
Journal:  Infect Immun       Date:  2009-04-27       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.